Market Overview:
The global granulomatosis with polyangiitis drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of granulomatosis with polyangiitis, rising awareness about the disease, and technological advancements in the field of drug development. The global granulomatosis with polyangiitis drug market is segmented on the basis of type, application, and region. On the basis of type, it is divided into benralizumab, avacopan, rituximab biosimilar (rituximab-GA), and others. Benralizumab held a dominant share in 2017 owing to its high efficacy and safety profile as compared to other drugs available in this market. On the basis of application, it is segmented into hospital pharmacies/clinics/outpatient settings/research centers and others. Hospital pharmacies are expected to hold a dominant share during the forecast period owing to their large customer base as well as growing demand for better healthcare services across regions.
Product Definition:
Granulomatosis with polyangiitis (GPA), formerly known as Wegener's granulomatosis, is a rare autoimmune disease that causes inflammation of the blood vessels. It typically affects the nose, sinuses, lungs, and kidneys. Granulomatosis with polyangiitis drug is an important treatment for this condition.
Benralizumab:
Benralizumab is a humanized monoclonal antibody that targets interleukin (IL) - 1 receptor subunit. IL-1R helps in the communication between cells of the immune system and it acts as an important growth factor for B cell, T cell, and natural killer (NK) cells. Benralizumab has been approved by the U.
Avacopan:
Avacopan is used in the treatment of granulomatosis with polyangiitis. It works by increasing the blood flow to the peripheral tissues and organs. Avacopan has been approved by both U.S.
Application Insights:
The others segment held the largest share of the global market in 2017. This is due to an increase in cases of Kawasaki disease and eosinophilic granulomatosis with polyangiitis.
Based on application, the global GRP-PA Drug Market has been segmented into hospital, clinic or outpatient setting and others such as primary care clinics/family medicine centers (FMCs).
Regional Analysis:
North America dominated the global granulomatosis with polyangiitis drug market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of target diseases are some factors responsible for its large share. In addition, the availability of highly effective treatment options is anticipated to drive regional growth during the forecast period.
Asia Pacific is expected to witness lucrative CAGR over the forecast period owing to rising healthcare expenditure by governments and private sectors in countries such as China & India along with other Southeast Asian nations. Moreover, growing awareness about GIA coupled with an increase in R&D initiatives by pharmaceutical companies will support regional growth during the same period.
Growth Factors:
- Increasing incidence of Granulomatosis with Polyangiitis (GPA) due to changing lifestyle and environmental factors.
- Growing awareness about the disease among people and healthcare professionals.
- Rising demand for better treatment options for Granulomatosis with Polyangiitis patients.
- Availability of novel drugs and therapies for the treatment of GPA will boost the market growth in future years.
- Technological advancements in drug delivery systems will offer new opportunities for market growth over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Granulomatosis with Polyangiitis Drug Market Research Report
By Type
Benralizumab, Avacopan, Rituximab Biosimilar, Others
By Application
Hospital, Clinic, Others
By Companies
Bionovis SA, Bristol-Myers Squibb Company, ChemoCentryx Inc, Coherus BioSciences Inc, Genor BioPharma Co Ltd, GlaxoSmithKline Plc, Iltoo Pharma, Panacea Biotec Ltd, Sandoz International GmbH, The International Biotechnology Center(IBC) Generium
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
184
Number of Tables & Figures
129
Customization Available
Yes, the report can be customized as per your need.
Global Granulomatosis with Polyangiitis Drug Market Report Segments:
The global Granulomatosis with Polyangiitis Drug market is segmented on the basis of:
Types
Benralizumab, Avacopan, Rituximab Biosimilar, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bionovis SA
- Bristol-Myers Squibb Company
- ChemoCentryx Inc
- Coherus BioSciences Inc
- Genor BioPharma Co Ltd
- GlaxoSmithKline Plc
- Iltoo Pharma
- Panacea Biotec Ltd
- Sandoz International GmbH
- The International Biotechnology Center(IBC) Generium
Highlights of The Granulomatosis with Polyangiitis Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Benralizumab
- Avacopan
- Rituximab Biosimilar
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Granulomatosis with Polyangiitis Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Granulomatosis with polyangiitis (GPA) is a rare, life-threatening autoimmune disease that affects the lungs. The disease is caused by an overactive immune system that attacks and destroys the lining of the airways (bronchioles). This can lead to breathing problems, pneumonia, and even death. Currently there is no cure for GPA, but treatments include medications to control symptoms and lung surgery if needed. Some people may also need a blood transfusion or a stem cell transplant to help fight the disease.
Some of the key players operating in the granulomatosis with polyangiitis drug market are Bionovis SA, Bristol-Myers Squibb Company, ChemoCentryx Inc, Coherus BioSciences Inc, Genor BioPharma Co Ltd, GlaxoSmithKline Plc, Iltoo Pharma, Panacea Biotec Ltd, Sandoz International GmbH, The International Biotechnology Center(IBC) Generium.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Granulomatosis with Polyangiitis Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Granulomatosis with Polyangiitis Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Granulomatosis with Polyangiitis Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Granulomatosis with Polyangiitis Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Granulomatosis with Polyangiitis Drug Market Size & Forecast, 2020-2028
4.5.1 Granulomatosis with Polyangiitis Drug Market Size and Y-o-Y Growth
4.5.2 Granulomatosis with Polyangiitis Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Benralizumab
5.2.2 Avacopan
5.2.3 Rituximab Biosimilar
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Granulomatosis with Polyangiitis Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Granulomatosis with Polyangiitis Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Benralizumab
9.6.2 Avacopan
9.6.3 Rituximab Biosimilar
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Benralizumab
10.6.2 Avacopan
10.6.3 Rituximab Biosimilar
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Benralizumab
11.6.2 Avacopan
11.6.3 Rituximab Biosimilar
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Benralizumab
12.6.2 Avacopan
12.6.3 Rituximab Biosimilar
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Benralizumab
13.6.2 Avacopan
13.6.3 Rituximab Biosimilar
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Granulomatosis with Polyangiitis Drug Market: Competitive Dashboard
14.2 Global Granulomatosis with Polyangiitis Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bionovis SA
14.3.2 Bristol-Myers Squibb Company
14.3.3 ChemoCentryx Inc
14.3.4 Coherus BioSciences Inc
14.3.5 Genor BioPharma Co Ltd
14.3.6 GlaxoSmithKline Plc
14.3.7 Iltoo Pharma
14.3.8 Panacea Biotec Ltd
14.3.9 Sandoz International GmbH
14.3.10 The International Biotechnology Center(IBC) Generium
